Background
Methods
Study population
Antiviral treatment and follow-up
Statistics
Results
Baseline characteristics
Variable | Value | |
---|---|---|
Patients, n | 233 | |
Male sex, n (%) | 182 | (78.11) |
Age, M (range) | 54 | (25–73) |
CTP class A/B/C, n (%) | 227/6/0 | (97.42/2.58/0) |
Tumor maximum size, cm, M (range) | 4.1 | (2.1–9.7) |
HBV DNA, log copies/ml | 3.9 | (3.0–5.1) |
HBeAg postive, n (%) | 164 | (70.39) |
Cirrhosis, n (%) | 96 | (41.20) |
AFP, ng/mL, M (range) | 103.7 | (7.8–1210) |
TBIL, mmol/L, M (range) | 5.87 | (2.60–64.70) |
ALT, IU/L, M (range) | 26 | (11–57) |
AST, IU/L, M (range) | 27 | (19–78) |
ALP, IU/L, M (range) | 51 | (45–187) |
ALB, g/L, M (range) | 3.9 | (2.3–5.7) |
PLT, 10^9/L, M (range) | 163.5 | (79–241) |
PT, s, M (range) | 12.1 | (11.3–13.6) |
INR, M (range) | 0.99 | (0.77–1.24) |
Variable | TDF | ETV |
P
| ||
---|---|---|---|---|---|
Patients, n (%) | 107 | (45.92) | 126 | (54.08) | |
Male sex, n (%) | 82 | (76.63) | 107 | (84.92) | 0.08 |
Age, M (range) | 52 | (25–69) | 55 | (26–73) | 0.31 |
CTP class A/B/C, n (%) | 0.11 | ||||
A | 105 | (98.13) | 122 | (96.82) | |
B | 2 | (1.87) | 4 | (3.18) | |
C | 0 | 0 | |||
HBV DNA, log copies/ml | 3.7 | (3.0–4.7) | 4.1 | (3.0–5.1) | 0.07 |
HBeAg postive, n (%) | 76 | (71.03) | 88 | (69.84) | 0.14 |
Cirrhosis, n (%) | 59 | (55.14) | 37 | (29.36) | 0.03 |
AFP, ng/mL, M (range) | 97.5 | (7.8–1210) | 109 | (10.3–1210) | 0.33 |
Tumor maximum size, cm, M (range) | 3.8 | (2.8–9.7) | 4.4 | (2.6–8.5) | |
TBIL, mmol/L, M (range) | 4.78 | (2.6–64.7) | 7.41 | (3.90–54.30) | 0.16 |
ALT, IU/L, M (range) | 21 | (11–41) | 27 | (19–57) | 0.11 |
AST, IU/L, M (range) | 28 | (19–56) | 21 | (20–78) | 0.41 |
ALP, IU/L, M (range) | 49 | (45–111) | 58 | (51–187) | 0.09 |
ALB, g/L, M (range) | 3.5 | (2.3–5.7) | 4.1 | (2.5–5.1) | 0.64 |
PLT, 10^9/L, M (range) | 134.24 | (79–241) | 183 | (99–210) | 0.21 |
PT, s, M (range) | 11.9 | (11.3–12.6) | 12.5 | (11.7–13.6) | 0.08 |
INR, M (range) | 1.01 | (0.77–1.24) | 0.97 | (0.81–1.21) | 0.51 |
Virological response and serum biomarker dynamics
Survival analysis
Predictors for disease-free survival
Univariant analysis | p-value | Multivariant analysis | p-value | |
---|---|---|---|---|
HR (95% CI) | HR (95% CI) | |||
Gender:male/female | 0.77 (0.37–1.59) | NS | ||
Child-Pugh score: A/B | 0.94 (0.32–1.61) | NS | ||
HBV DNA ≤ 4 (log copies/mL) | 0.71 (0.33–1.54) | NS | ||
HBeAg: negative/positive | 0.61 (0.11–0.91) | < 0.05 | ||
Non-cirrhosis/Cirrhosis | 0.47 (0.21–0.98) | < 0.05 | 0.41 (0.13–0.77) | < 0.05 |
Total bilirubin: < 24/≥ 24 (μmol/L) | 1.15 (0.69–1.91) | NS | ||
TDF treatment/ETV treatment | 0.78 (0.43–0.97) | < 0.05 | 0.35 (0.33–0.84) | < 0.05 |